Biotech Values

[Double_Bagel]

FDA Approves Baxter’s HYQVIA for Treatment of Adults with Primary Immunodeficiency

http://finance.yahoo.com/news/fda-approves-baxter-hyqvia-treatment-230200320.html

Baxter International Inc. (BAX) and Halozyme Therapeutics, Inc., (HALO) today announced that the United States Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency (PI), HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase].

HYQVIA is the first subcutaneous immune globulin (IG) treatment approved for PI patients with a dosing regimen requiring only one infusion up to once per month (every three to four weeks) and one injection site per infusion to deliver a full therapeutic dose of IG. The majority of PI patients today receive intravenous infusions in a doctor’s office or infusion center, and current subcutaneous IG treatments require weekly or bi-weekly treatment with multiple infusion sites per treatment.

Still 18 million shorts in HALO. I will enjoy watching them cover at some point in the coming months

http://www.nasdaq.com/symbol/halo/short-interest

HALO should be getting $37 million in milestone payments from Baxter for this approval.

http://google.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=5424218-3908-6665&type=sect&TabIndex=2&companyid=91019&ppu=%252fdefault.aspx%253fsym%253dHALO